Luke Halpern, Associate Editor

Replacing carmustine with cisplatin in BEAM ((carmustine, etoposide, cytarabine, and melphalan) conditioning could be more cost-effective for patients.

Two different brands of intravenous immunoglobulin have been investigated, finding Brand P led to significantly longer durations of fever and hospitalization when compared to brand T.

Chris Peshek of Discount Drug Mart discusses the importance of community pharmacies and the process of building relationships with patients, and how a profession in the field can be rewarding for those seeking to pursue it.

The trial is evaluating the success of BNT111 and cemiplimab in treating unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment.

In the first half of 2024, the FDA approved 23 novel drugs for conditions including alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more.

Investigators determine the efficacy and safety of the combination in a 2-phase trial.

In an analysis of 16 immunocompromised patients with COVID-19, intravenous immunoglobulin was effective and associated with clinical cure.

Afami-cel was approved in conjunction with MAGE-A4 IHC 1F9 pharmDx, a diagnostic tool that can identify patients eligible to receive the treatment for synovial sarcoma.

The RUBY trial will continue and analyze the overall population survival after treatment with the drug combination.

The presence of glutamic acid decarboxylase antibodies in intravenous immunoglobulin can lead to a misdiagnosis of type 1 diabetes mellitus if a false-positive result is garnered.

The designation is based off positive results from the RAMP 205 trial presented at the ASCO Annual Meeting.

Immunization rates have not returned to pre-pandemic levels, leaving millions of children and infants at risk for measles or diphtheria, tetanus, and pertussis.

A lack of widespread hepatitis B screenings compound with the issue of inaccurate test results, which can complicate treatment with intravenous immunoglobulin.

The new approach could optimize precision medicine and lead to better outcomes across a variety of disease states.

The FDA’s designation builds off positive results in a phase 1b/2a clinical trial, showing that the vaccine can effectively target the Tau protein.

Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.

Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.

It is essential for clinicians to properly diagnose patients with suspected AVWS and provide them proper treatment, which could be intravenous immunoglobulin.

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

Eculizumab-aagh does not have an interchangeable designation, though that could be updated in the future.

There were positive efficacy and safety results for tivozanib monotherapy consistent with previous analyses.

In a study of Swedish patients with mantle cell lymphoma, the participants faced a heightened risk of infection after their diagnosis and associated treatment for the disease.

The cause of the outage was deemed to be due to a defect found in a content update for Windows users.

A large portion of the population of patients in the United States with GERD have the non-erosive type of the disease.

A patient with severe and recurrent pemphigus vulgaris achieved lasting remission with a novel intravenous immunoglobulin preparation that had the added benefit of reducing treatment-related side effects.

Investigators compared the criteria for eligibility in the VICTORIA trial with guideline and label criterion, finding a wider than expected population with heart failure were eligible for vericiguat therapy.

Allison Burns discusses how pharmacists should prepare and educate themselves regarding OTC naloxone, and the steps that can be taken in stores and pharmacies to ensure OTC naloxone is visible and available.

Allison Burns, president and CEO of EMO Health, discusses the price point and stigma surrounding OTC naloxone in an interview with Pharmacy Times.

An analysis of interaction checkers and product summaries revealed large differences in the consistency and reliability of providing accurate information on potential drug-drug interactions.

In pediatric and adult patients, the top 3 surgical procedures accounted for the highest share of opioid prescriptions, indicating a need for better opioid prescription management and greater awareness of the possible opioid-related adverse events that can stem from prescriptions of the drug.